Overview

PT003 MDI Cardiovascular Safety Study

Status:
Completed

Trial end date:
2011-11-01

Target enrollment:

Participant gender:

Summary

This study is primarily a safety study. The primary and secondary endpoints are based on 24-hour Holter monitor assessments obtained on Day 14 relative to baseline.

Phase:

Phase 2

Details

Lead Sponsor:

Pearl Therapeutics, Inc.

Treatments:

Formoterol Fumarate